Globus Medical (GMED) Competitors

Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.

Which has more volatility and risk, GMED or RMD?

Globus Medical has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Is GMED or RMD more profitable?

ResMed has a net margin of 25.34% compared to Globus Medical's net margin of 4.09%. ResMed's return on equity of 26.17% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	4.09%	10.83%	8.63%
ResMed	25.34%	26.17%	18.60%

Which has stronger valuation & earnings, GMED or RMD?

ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.52B	3.95	$122.87M	$0.75	96.38
ResMed	$4.93B	6.38	$1.02B	$8.47	25.26

Does the MarketBeat Community believe in GMED or RMD?

Globus Medical received 140 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 67.33% of users gave Globus Medical an outperform vote while only 52.74% of users gave ResMed an outperform vote.

Company	Underperform	Outperform
Globus Medical	Outperform Votes 573 67.33%	Underperform Votes 278 32.67%
ResMed	Outperform Votes 433 52.74%	Underperform Votes 388 47.26%

Do analysts prefer GMED or RMD?

Globus Medical presently has a consensus target price of $96.91, indicating a potential upside of 34.06%. ResMed has a consensus target price of $249.73, indicating a potential upside of 16.70%. Given Globus Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Globus Medical is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
ResMed	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.67

Do institutionals and insiders believe in GMED or RMD?

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 18.5% of Globus Medical shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer GMED or RMD?

In the previous week, ResMed had 4 more articles in the media than Globus Medical. MarketBeat recorded 27 mentions for ResMed and 23 mentions for Globus Medical. ResMed's average media sentiment score of 1.50 beat Globus Medical's score of 1.01 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	11 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	22 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

ResMed beats Globus Medical on 10 of the 19 factors compared between the two stocks.